TABLE 1.
Demographics features of COVID‐19 patients on admission to hospital
| All patients (n = 408) | At least one additional pathogen (n = 52) | No additional pathogen detection (n = 356) | p value | |
|---|---|---|---|---|
| Median (IQR) age, years | 48.0 (34.0‐60.0) | 54.5 (35.0‐65.25) | 47.0 (34.0‐59.0) | 0.32 |
| Gender, male | 196 (48.0) | 26 (50.0) | 170 (47.8) | 0.76 |
| Comorbidity | 106 (26.0) | 18 (34.6) | 88 (24.7) | 0.13 |
| Hypertension | 53 (13.0) | 10 (19.2) | 43 (12.1) | 0.15 |
| Diabetes | 22 (5.4) | 6 (11.5) | 16 (4.5) | 0.036 |
| Cardiovascular diseases | 15 (3.7) | 3 (5.8) | 12 (3.4) | 0.42 |
| Cancer | 7 (1.7) | 0 (0) | 7 (2.0) | 0.60 |
| Others | 35 (8.6) | 6 (11.5) | 29 (8.1) | 0.41 |
| Symptoms at admission | 357 (87.5) | 47 (90.4) | 310 (87.1) | 0.65 |
| Median (IQR) days from onset to admission | 3 (1‐6) | 3 (2‐5.25) | 3 (1‐6) | 0.33 |
| Severity group | ||||
| Mild and moderate | 319 (78.2) | 30 (57.7) | 289 (81.2) | <0.001 |
| Severe ill | 71 (17.4) | 7 (13.5) | 64 (18.0) | 0.56 |
| Critically ill | 18 (4.4) | 15 (28.8) | 3 (0.8) | <0.001 |
| Treatment | ||||
| Oxygen therapy | 138 (33.8) | 24 (46.1) | 114 (32.0) | 0.044 |
| Antibiotic treatment | 60 (14.7) | 34 (65.4) | 26 (7.3) | <0.001 |
| Antiviral treatment | 408 (100) | 52 (100) | 356 (100) | >0.99 |
| Blood routine | ||||
| Leukocyte count (×10⁹/L) | 4.7 (3.8‐5.9) | 4.8 (4.0‐6.3) | 4.6 (3.8‐5.9) | 0.26 |
| >10 × 10⁹/L | 11 (2.7) | 3 (5.8) | 8 (2.2) | 0.15 |
| <4 × 10⁹/L | 122 (29.9) | 13 (25) | 109 (30.6) | 0.40 |
| Lymphocyte count (×10⁹/L) | 1.3 (1.0‐1.8) | 1.2 (0.9‐1.7) | 1.3 (1.0‐1.8) | 0.14 |
| <1.5 × 10⁹/L | 256 (62.7) | 36 (69.2) | 220 (61.8) | 0.31 |
| Platelet count | 186.0 (148.0‐233.0) | 171.0 (128.0‐228.5) | 188.0 (150.0‐234.0) | 0.070 |
| <150 × 10⁹/L | 107 (26.2) | 20 (38.5) | 87 (24.4) | 0.032 |
| Hemoglobin (g/L) | 137.0 (126.0‐147.0) | 135.5 (123.3‐145.0) | 137.0 (127.0‐147.0) | 0.18 |
| Coagulation function | ||||
| d‐dimer (μg/L) | 0.4 (0.3‐0.5) | 0.5 (0.3‐1.0) | 0.4 (0.2‐0.5) | 0.0012 |
| ≥0.5 μg/L | 127 (31.1) | 23 (44.2) | 104 (29.2) | 0.026 |
| Infection‐related biomarkers | ||||
| C‐reactive protein (mg/L) | 9.5 (4.1‐25.1) | 11.2 (3.2‐28.3) | 9.4 (4.3‐25.0) | 0.57 |
| ≥10 mg/L, n = 393 | 197 (48.3) | 27 (51.9) | 170 (47.8) | 0.63 |
| IL‐6 (pg/ml) (n = 348/47/301) | 9.6 (3.9‐19.4) | 19.1 (5.3‐36.1) | 8.8 (3.8‐17.4) | 0.0027 |
| ≥7 pg/ml, n = 326 | 190 (54.6) | 32 (68.1) | 158 (52.5) | 0.046 |
| Procalcitonin (ng/ml) | 0.0 (0.0‐0.1) | 0.1 (0.0‐0.1) | 0.0 (0.0‐0.1) | 0.0002 |
| ≥0.25 ng/ml, n = 385 | 6 (1.5) | 3 (5.8) | 3 (0.8) | 0.03 |
| Clinical outcomes a | ||||
| Remained in hospital | 13 (3.2) | 6 (11.5) | 7 (2.0) | 0.0002 |
| Discharged | 392 (96.1) | 43 (82.7) | 349 (98.0) | <0.001 |
| Median (IQR) duration of hospitalization | 20.0 (15.0‐27.0) | 20.0 (14.0‐27.0) | 20.0 (15.0‐27.0) | 0.84 |
| Died | 3 (0.7) | 3 (5.8) | 0 (0) | 0.002 |
Data are no. (%) and median (IQR).
a
Clinical outcomes were recorded till 16 March 2020.